This Article Full Text Full Text (PDF) All Versions of this Article: 114/5/397    most recent CIRCULATIONAHA.106.628347v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmed, A. Articles by Gheorghiade, M. Search for Related Content PubMed PubMed Citation Articles by Ahmed, A. Articles by Gheorghiade, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DIGOXIN Medline Plus Health Information Heart Failure Related Collections Other heart failure Congestive

(Circulation. 2006;114:397-403.)
© 2006 American Heart Association, Inc.

Heart Failure

Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure

The Ancillary Digitalis Investigation Group Trial

Ali Ahmed, MD, MPH; Michael W. Rich, MD; Jerome L. Fleg, MD; Michael R. Zile, MD; James B. Young, MD; Dalane W. Kitzman, MD; Thomas E. Love, PhD; Wilbert S. Aronow, MD; Kirkwood F. Adams, Jr, MD; Mihai Gheorghiade, MD

From the University of Alabama at Birmingham, and VA Medical Center, Birmingham (A.A.); Washington University, St Louis, Mo (M.W.R.); National Heart, Lung, and Blood Institute, Bethesda, Md (J.L.F.); Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston (M.R.Z.); Cleveland Clinic Foundation, Cleveland, Ohio (J.B.Y.); Wake-Forest University, Winston-Salem, NC (D.W.K.); Case Western Reserve University, Cleveland, Ohio (T.E.L.); New York Medical College, Valhalla (W.S.A.); University of North Carolina, Chapel Hill (K.F.A.); and Northwestern University, Chicago, Ill (M.G.).

Reprint requests to Ali Ahmed, MD, MPH, University of Alabama at Birmingham, 1530 3rd Ave S, CH-19, Suite 219, Birmingham AL 35294-2041. E-mail aahmed{at}uab.edu

Received February 7, 2006; de novo received March 21, 2006; revision received April 12, 2006; accepted May 1, 2006.

Background— About half of the 5 million heart failure patients in the United States have diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction). Except for candesartan, no drugs have been tested in randomized clinical trials in these patients. Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published.

Methods and Results— Ambulatory chronic heart failure patients (n=988) with normal sinus rhythm and ejection fraction >45% (median, 53%) from the United States and Canada (1991 to 1993) were randomly assigned to digoxin (n=492) or placebo (n=496). During follow-up with a mean length of 37 months, 102 patients (21%) in the digoxin group and 119 patients (24%) in the placebo group (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.63 to 1.07; P=0.136) experienced the primary combined outcome of heart failure hospitalization or heart failure mortality. Digoxin had no effect on all-cause or cause-specific mortality or on all-cause or cardiovascular hospitalization. Use of digoxin was associated with a trend toward a reduction in hospitalizations resulting from worsening heart failure (HR, 0.79; 95% CI, 0.59 to 1.04; P=0.094) but also a trend toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P=0.061).

Conclusions— In ambulatory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receiving angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end points such as mortality and all-cause or cardiovascular hospitalizations.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				D. J. van Veldhuisen, A. Cohen-Solal, M. Bohm, S. D. Anker, D. Babalis, M. Roughton, A. J.S. Coats, P. A. Poole-Wilson, M. D. Flather, and SENIORS Investigators Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J. Am. Coll. Cardiol., June 9, 2009; 53(23): 2150 - 2158. [Abstract] [Full Text] [PDF]

				K. Tzanetos, D. Leong, and R. C. Wu Office management of patients with diastolic heart failure Can. Med. Assoc. J., March 3, 2009; 180(5): 520 - 527. [Full Text] [PDF]

				J. Wang and S. F. Nagueh Current Perspectives on Cardiac Function in Patients With Diastolic Heart Failure Circulation, March 3, 2009; 119(8): 1146 - 1157. [Full Text] [PDF]

				M. Gheorghiade and P. S. Pang Acute heart failure syndromes. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573. [Abstract] [Full Text] [PDF]

				M. Metra, L. Dei Cas, and B. M. Massie Treatment of heart failure in the elderly: never say it's too late Eur. Heart J., February 2, 2009; 30(4): 391 - 393. [Full Text] [PDF]

				A. A. Alsaddique, A. G. Royse, C. F. Royse, and M. A. Fouda Management of diastolic heart failure following cardiac surgery Eur. J. Cardiothorac. Surg., February 1, 2009; 35(2): 241 - 249. [Abstract] [Full Text] [PDF]

				J. D. Flaherty, J. J. Bax, L. De Luca, J. S. Rossi, C. J. Davidson, G. Filippatos, P. P. Liu, M. A. Konstam, B. Greenberg, M. R. Mehra, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J. Am. Coll. Cardiol., January 20, 2009; 53(3): 254 - 263. [Abstract] [Full Text] [PDF]

				S. J. Shah and M. Gheorghiade Heart Failure With Preserved Ejection Fraction: Treat Now by Treating Comorbidities JAMA, July 23, 2008; 300(4): 431 - 433. [Full Text] [PDF]

				J. J.V. McMurray, P. E. Carson, M. Komajda, R. McKelvie, M. R. Zile, A. Ptaszynska, C. Staiger, J. M. Donovan, and B. M. Massie Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial Eur J Heart Fail, February 1, 2008; 10(2): 149 - 156. [Abstract] [Full Text] [PDF]

				G. C. Fonarow, W. G. Stough, W. T. Abraham, N. M. Albert, M. Gheorghiade, B. H. Greenberg, C. M. O'Connor, J. L. Sun, C. W. Yancy, J. B. Young, et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure: A Report From the OPTIMIZE-HF Registry J. Am. Coll. Cardiol., August 21, 2007; 50(8): 768 - 777. [Abstract] [Full Text] [PDF]

				A. Ahmed Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 323 - 329. [Abstract] [Full Text] [PDF]

				C. A. Fiack, H. W. Farber, M. A. Arias, A. Alonso-Fernandez, F. Garcia-Rio, K. M. Kessler, A. Ahmed, J. L. Fleg, M. Gheorghiade, T. E. Owan, et al. Heart failure with preserved ejection fraction. N. Engl. J. Med., October 26, 2006; 355(17): 1828 - 1828. [Full Text] [PDF]

				J. G.F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor, and on behalf of PEP-CHF Investigators The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur. Heart J., October 1, 2006; 27(19): 2338 - 2345. [Abstract] [Full Text] [PDF]

				J. McMurray Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger Eur. Heart J., October 1, 2006; 27(19): 2257 - 2259. [Full Text] [PDF]

				No Benefit of Digoxin for HF with Preserved LV Function Journal Watch Cardiology, August 16, 2006; 2006(816): 3 - 3. [Full Text]